Computer-Based Training for Mild Alzheimer’s Disease - Full Text View

Purpose

The primary objective of this study is to evaluate the effects of computer-based training program (“HiFi-AD”) on the memory and cognitive abilities of individuals diagnosed with mild Alzheimer’s Disease (AD).

Condition	Intervention	Phase
Alzheimer's Disease	Procedure: Computer-based Cognitive Training	Phase I

Genetics Home Reference related topics:

Alzheimer disease

MedlinePlus related topics:

Alzheimer's Disease Dementia

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study

Official Title:	Computer-Based Training for Mild Cognitive Impairment and Mild Alzheimer’s Disease

Further study details as provided by Posit Science Corporation:

Primary Outcome Measures:

The primary objective of this trial will be to assess the feasibility of using computer-based
cognitive training in an a population with early Alzheimer's Disease.

Secondary Outcome Measures:

A standardized set of neuropsychological assessments will be conducted pre- and post-
compuer-based training.

Estimated Enrollment:	6
Study Start Date:	September 2004
Estimated Study Completion Date:	October 2006

Detailed Description:

The purpose of this study is to determine the extent to which computer-based cognitive remediation improves cognitive functions using standardized neuropsychological assessments relevant to AD; 2) the acceptability and feasibility of using computer-based cognitive remediation in an AD population.

Eligibility

Ages Eligible for Study:	60 Years to 90 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Fluent in English.
Mini-Mental Status Examination (MMSE) score of 22 or higher.
Adequate visual capacity.
Adequate hearing capacity.
Has a caregiver with some computer experience.
Willing and able to commit to the time requirement of the entire study.

Exclusion Criteria:

Clinically significant cerebrovascular disease.
Participant is planning to begin acetylcholinesterase inhibitor (AChEI) therapy.
Participants with severe tremor.
Axis 1 or 2 psychiatric disorders.
History of substance abuse.
History of head trauma.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00319891

Locations


United States, California
	University of California, San Francisco
	San Francisco, California, United States, 94143

Sponsors and Collaborators

Posit Science Corporation

University of California, San Francisco

Investigators


Principal Investigator:	Joel Kramer, PsyD	University of California, San Francisco

Principal Investigator:	Kristine Yaffe, MD	University of California, San Francisco

More Information

Study ID Numbers:	OUT-109-2005
First Received:	April 27, 2006
Last Updated:	April 27, 2006
ClinicalTrials.gov Identifier:	NCT00319891
Health Authority:	United States: Food and Drug Administration

Keywords provided by Posit Science Corporation:

Alzheimer's

AD

Mild Cognitive Impairment

Dementia

Cognitive remediation

computer-based training

Study placed in the following topic categories:

Delirium, Dementia, Amnestic, Cognitive Disorders

Mental Disorders

Alzheimer Disease

Central Nervous System Diseases

Neurodegenerative Diseases

Brain Diseases

Dementia

Cognition Disorders

Delirium

Additional relevant MeSH terms:

Nervous System Diseases

Tauopathies

ClinicalTrials.gov processed this record on October 06, 2008

Sponsors and Collaborators:	Posit Science Corporation University of California, San Francisco
Information provided by:	Posit Science Corporation
ClinicalTrials.gov Identifier:	NCT00319891